Lotrafilcon A contact lenses
DeviceCE-marked silicone hydrogel contact lenses
Other names: Air Optix® Night and Day® Aqua, AONDA
NCT Number: NCT05992675
The purpose of this retrospective, Post-Market Clinical Follow-Up (PMCF) study is to assess the long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as 30 days of continuous wear for vision correction.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Complete Family Vision Care, San Diego, California, United States
This is a non-interventional/observational study designed as a retrospective chart review. Study sites will identify charts within their existing databases in a fair and consistent manner. Subjects/charts meeting the eligibility criteria will be enrolled in the study.
The study is designed with one period. The duration of the period includes the Baseline Visit and the Year 3 Visit as follows:
The data collection period is defined as any approximately 3-year timeframe since and including 2009.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
CE-marked silicone hydrogel contact lenses
Other names: Air Optix® Night and Day® Aqua, AONDA
CE-marked silicone hydrogel contact lenses
Other names: PureVision® 2, PV2
Time frame: Year 3
The subject's chart will be reviewed for distance visual acuity.
Time frame: Up to Year 3
The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the Baseline Visit exam.
Time frame: Up to Year 3
The subject's chart will be reviewed for incidences of microbial keratitis occurring after the Baseline Visit exam.
Alcon Research
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07570602
Eye Diseases, Presbyopia
Bloomington, Indiana, United States
View Trial DetailsNCT07614113
Eye Diseases, Myopia
Faisalābad, Punjab Province, Pakistan
View Trial DetailsNCT06668246
Ametropia, Eye Diseases
Brest, France
View Trial DetailsNCT05059041
Abnormalities, Multiple, Chromosome Disorders
Columbus, Ohio, United States
View Trial Details